252 related articles for article (PubMed ID: 37097545)
41. Long-term follow-up after rituximab plus bendamustine in a patient with relapsed or refractory hairy cell leukemia variant: A case report.
Imoto N; Koyama D; Sugiura I; Kurahashi S
Medicine (Baltimore); 2021 Feb; 100(5):e24457. PubMed ID: 33592897
[TBL] [Abstract][Full Text] [Related]
42. Hairy cell leukemia: update and current therapeutic approach.
Salam L; Abdel-Wahab O
Curr Opin Hematol; 2015 Jul; 22(4):355-61. PubMed ID: 26049757
[TBL] [Abstract][Full Text] [Related]
43. [Novelties in the diagnostics and therapy of hairy cell leukemia].
Sári E; Rajnai H; Dénes K; Bödör C; Csomor J; Körösmezey G; Tárkányi I; Eid H; Nagy Z; Demeter J
Magy Onkol; 2016 Jun; 60(2):137-44. PubMed ID: 27275640
[TBL] [Abstract][Full Text] [Related]
44. Hairy cell leukemia: a successful model for experimental therapeutics--pentostatin and new ideas.
Grever MR
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():25-8. PubMed ID: 21599604
[TBL] [Abstract][Full Text] [Related]
45. [Recurrent somatic mutation in hairy cell leukemia].
Sári E; Nagy Z; Demeter J
Orv Hetil; 2013 Jan; 154(4):123-7. PubMed ID: 23335721
[TBL] [Abstract][Full Text] [Related]
46. [Clinical and molecular characteristics and prognosis of classical hairy cell leukemia and hairy cell leukemia variant].
Wei C; Jin XX; Cai H; Wang X; Zhuang JL; Zhou DB
Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):416-421. PubMed ID: 37032137
[No Abstract] [Full Text] [Related]
47. Hairy cell leukemia: an elusive but treatable disease.
Wanko SO; de Castro C
Oncologist; 2006; 11(7):780-9. PubMed ID: 16880237
[TBL] [Abstract][Full Text] [Related]
48. Long-term follow-up studies in hairy cell leukemia.
Grever MR; Zinzani PL
Leuk Lymphoma; 2009 Oct; 50 Suppl 1():23-6. PubMed ID: 19814694
[TBL] [Abstract][Full Text] [Related]
49. Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population.
Madanat YF; Rybicki L; Radivoyevitch T; Jagadeesh D; Dean R; Pohlman B; Kalaycio M; Sekeres MA; Smith MR; Hill BT
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):857-862. PubMed ID: 28778620
[TBL] [Abstract][Full Text] [Related]
50. Immunoconjugates and new molecular targets in hairy cell leukemia.
Kreitman RJ
Hematology Am Soc Hematol Educ Program; 2012; 2012():660-6. PubMed ID: 23233649
[TBL] [Abstract][Full Text] [Related]
51. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.
Chihara D; Kantarjian H; O'Brien S; Jorgensen J; Pierce S; Faderl S; Ferrajoli A; Poku R; Jain P; Thompson P; Brandt M; Luthra R; Burger J; Keating M; Ravandi F
Br J Haematol; 2016 Sep; 174(5):760-6. PubMed ID: 27301277
[TBL] [Abstract][Full Text] [Related]
52. Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders.
Maitre E; Paillassa J; Troussard X
Front Oncol; 2022; 12():1068981. PubMed ID: 36620555
[TBL] [Abstract][Full Text] [Related]
53. Hairy cell leukemia: towards a curative strategy.
Gidron A; Tallman MS
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1153-62. PubMed ID: 16990114
[TBL] [Abstract][Full Text] [Related]
54. Concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and hairy cell leukemia: clinical, pathologic and molecular features.
Obiorah IE; Francischetti IMB; Wang HW; Ahn IE; Wang W; Raffeld M; Kreitman RJ; Wiestner A; Calvo KR
Leuk Lymphoma; 2020 Dec; 61(13):3177-3187. PubMed ID: 32755330
[TBL] [Abstract][Full Text] [Related]
55. Chemo-immunotherapy for hairy cell leukemia.
Ravandi F
Leuk Lymphoma; 2011 Jun; 52 Suppl 2(0 2):72-4. PubMed ID: 21417822
[TBL] [Abstract][Full Text] [Related]
56. Hairy cell leukemia: Update on molecular profiling and therapeutic advances.
Grever MR; Blachly JS; Andritsos LA
Blood Rev; 2014 Sep; 28(5):197-203. PubMed ID: 25110197
[TBL] [Abstract][Full Text] [Related]
57. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
[TBL] [Abstract][Full Text] [Related]
58. Moxetumomab pasudotox for the treatment of relapsed and/or refractory hairy cell leukemia.
Abou Dalle I; Ravandi F
Expert Rev Hematol; 2019 Sep; 12(9):707-714. PubMed ID: 31298972
[No Abstract] [Full Text] [Related]
59. [Molecular and therapeutic advances in Hairy cell leukemia].
Balsat M; Cornillon J
Bull Cancer; 2013 Oct; 100(10):1043-7. PubMed ID: 24103785
[TBL] [Abstract][Full Text] [Related]
60. Current and emerging treatment options for hairy cell leukemia.
López-Rubio M; Garcia-Marco JA
Onco Targets Ther; 2015; 8():2147-56. PubMed ID: 26316784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
